J&J's multiple myeloma drug reduces risk of death in late-stage study
December 04, 2018 at 10:30 AM EST
Johnson & Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday.